伏立康唑、氟康唑和伊曲康唑对来自美国和非洲的566株新生隐球菌临床分离株的体外活性。
In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.
作者信息
Pfaller M A, Zhang J, Messer S A, Brandt M E, Hajjeh R A, Jessup C J, Tumberland M, Mbidde E K, Ghannoum M A
机构信息
Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA.
出版信息
Antimicrob Agents Chemother. 1999 Jan;43(1):169-71. doi: 10.1128/AAC.43.1.169.
Abstract
We investigated the in vitro activity of voriconazole compared to those of fluconazole and itraconazole against 566 clinical isolates of Cryptococcus neoformans from Africa (164) and the United States (402). Isolates were obtained from cerebrospinal fluid (362), blood (139), and miscellaneous sites (65). Voriconazole (MIC at which 90% of the isolates are inhibited [MIC90], 0.12 to 0.25 microg/ml) was more active than either itraconazole (MIC90, 0.5 microg/ml) or fluconazole (MIC90, 8.0 to 16 microg/ml) against both African and U. S. isolates. Isolates inhibited by >/=16 microg of fluconazole per ml were almost all (99%) inhibited by </=1 microg of voriconazole per ml. These results suggest that voriconazole may be useful in the treatment of cryptococcosis.
摘要
我们研究了伏立康唑与氟康唑和伊曲康唑相比，对来自非洲（164株）和美国（402株）的566株新生隐球菌临床分离株的体外活性。分离株取自脑脊液（362株）、血液（139株）和其他部位（65株）。伏立康唑（对90%分离株产生抑制作用的最低抑菌浓度[MIC90]为0.12至0.25微克/毫升）对非洲和美国的分离株的活性均高于伊曲康唑（MIC90为0.5微克/毫升）或氟康唑（MIC90为8.0至16微克/毫升）。每毫升氟康唑抑制浓度≥16微克的分离株几乎全部（99%）被每毫升伏立康唑抑制浓度≤1微克所抑制。这些结果表明伏立康唑可能对治疗隐球菌病有用。
相似文献
1
In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.伏立康唑、氟康唑和伊曲康唑对来自美国和非洲的566株新生隐球菌临床分离株的体外活性。
Antimicrob Agents Chemother. 1999 Jan;43(1):169-71. doi: 10.1128/AAC.43.1.169.
2
In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates.伏立康唑和伊曲康唑对氟康唑敏感及耐药新生隐球菌分离株的体外比较疗效
Antimicrob Agents Chemother. 1998 Feb;42(2):471-2. doi: 10.1128/AAC.42.2.471.
3
Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.巴西戈亚斯州戈亚尼亚市新型隐球菌临床和环境分离株的抗真菌药敏性
Rev Inst Med Trop Sao Paulo. 2005 Sep-Oct;47(5):253-6. doi: 10.1590/s0036-46652005000500003. Epub 2005 Nov 16.
4
Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.西班牙1994 - 1996年及1997 - 2005年HIV感染患者中新型隐球菌分离株对氟康唑、伊曲康唑和伏立康唑的抗真菌药敏情况
Chemotherapy. 2007;53(4):300-5. doi: 10.1159/000102585. Epub 2007 May 10.
5
In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans.雷夫康唑（BMS-207147）对541株新型隐球菌临床分离株的体外活性。
Antimicrob Agents Chemother. 2000 Oct;44(10):2883-6. doi: 10.1128/AAC.44.10.2883-2886.2000.
6
In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole.来自土耳其的新生隐球菌新生变种环境分离株对六种抗真菌药物（包括SCH56592和伏立康唑）的体外敏感性
Eur J Clin Microbiol Infect Dis. 2000 Apr;19(4):317-9. doi: 10.1007/s100960050484.
7
In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia.两性霉素B、氟康唑和伏立康唑对来自非洲和柬埔寨的162株新型隐球菌分离株的体外活性。
Eur J Clin Microbiol Infect Dis. 2004 Jun;23(6):506-8. doi: 10.1007/s10096-004-1136-2. Epub 2004 May 13.
8
Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.伏立康唑III期临床研究中，伏立康唑、伊曲康唑、氟康唑和两性霉素B对472例患者的1763株酵母菌的体外活性。
Int J Antimicrob Agents. 2008 Dec;32(6):511-4. doi: 10.1016/j.ijantimicag.2008.05.023. Epub 2008 Sep 13.
9
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.新型隐球菌-格特隐球菌种复合体：氟康唑、伊曲康唑、泊沙康唑和伏立康唑野生型药敏终点分布和流行病学折点的国际研究。
Antimicrob Agents Chemother. 2012 Nov;56(11):5898-906. doi: 10.1128/AAC.01115-12. Epub 2012 Sep 4.
10
In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.伏立康唑（UK-109,496）及其他四种抗真菌药物对394株念珠菌属临床分离株的体外活性
Antimicrob Agents Chemother. 1998 Jan;42(1):161-3. doi: 10.1128/AAC.42.1.161.
引用本文的文献
1
Amphotericin B plus fluorocytosine combined with voriconazole for the treatment of non-HIV and non-transplant-associated cryptococcal meningitis: a retrospective study.两性霉素 B 联合氟胞嘧啶与伏立康唑联合治疗非 HIV 和非移植相关隐球菌性脑膜炎：一项回顾性研究。
BMC Neurol. 2022 Jul 22;22(1):274. doi: 10.1186/s12883-022-02803-1.
2
Antifungal Susceptibility Profiles of var. and Clinical Isolates in Guangxi, Southern China.中国南方广西地区[具体菌株名称]变种及临床分离株的抗真菌药敏谱
Front Microbiol. 2021 Aug 10;12:708280. doi: 10.3389/fmicb.2021.708280. eCollection 2021.
3
Voriconazole as a secondary prophylaxis for cryptococcal meningitis during hematopoietic stem cell transplantation.伏立康唑作为造血干细胞移植期间隐球菌性脑膜炎的二线预防用药。
IDCases. 2021 Jul 26;25:e01241. doi: 10.1016/j.idcr.2021.e01241. eCollection 2021.
4
The Antifungal Activity of HMA, an Amiloride Analog and Inhibitor of Na/H Exchangers.氨氯吡脒类似物HMA（钠/氢交换体抑制剂）的抗真菌活性
Front Microbiol. 2021 May 5;12:673035. doi: 10.3389/fmicb.2021.673035. eCollection 2021.
5
Cryptococcosis in Patients following Kidney Transplantation: A 9-Year Retrospective Clinical Analysis at a Chinese Tertiary Hospital.肾移植术后患者隐球菌病：中国一家三级医院 9 年回顾性临床分析。
Biomed Res Int. 2019 Nov 11;2019:7165160. doi: 10.1155/2019/7165160. eCollection 2019.
6
Successful treatment with voriconazole combined with amphotericin B-liposome for fluconazole-resistant pulmonary cryptococcosis after renal transplantation.伏立康唑联合两性霉素B脂质体成功治疗肾移植后氟康唑耐药的肺隐球菌病。
CEN Case Rep. 2019 Nov;8(4):261-265. doi: 10.1007/s13730-019-00403-6. Epub 2019 Jun 3.
7
Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients.免疫功能低下患者中对氟康唑最低抑菌浓度升高的新型隐球菌性脑膜炎的回顾性研究
Open Forum Infect Dis. 2016 Apr 7;3(2):ofw076. doi: 10.1093/ofid/ofw076. eCollection 2016 Apr.
8
Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.印度中部中央邦贾巴尔普尔市临床和环境来源的新型隐球菌及格特隐球菌分离株的抗真菌药敏性
Braz J Microbiol. 2015 Oct-Dec;46(4):1125-33. doi: 10.1590/S1517-838246420140564. Epub 2015 Oct 27.
9
Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.乌干达新型隐球菌临床分离株中抗真菌药物耐药性增加。
Antimicrob Agents Chemother. 2015 Dec;59(12):7197-204. doi: 10.1128/AAC.01299-15. Epub 2015 Aug 31.
10
New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis.新型隐球菌性脑膜炎的预防、诊断和治疗新视角。
Curr HIV/AIDS Rep. 2012 Sep;9(3):267-77. doi: 10.1007/s11904-012-0127-7.
本文引用的文献
1
In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates.伏立康唑和伊曲康唑对氟康唑敏感及耐药新生隐球菌分离株的体外比较疗效
Antimicrob Agents Chemother. 1998 Feb;42(2):471-2. doi: 10.1128/AAC.42.2.471.
2
Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe.
Clin Infect Dis. 1998 Feb;26(2):284-9. doi: 10.1086/516298.
3
The hidden danger of primary fluconazole prophylaxis for patients with AIDS.艾滋病患者氟康唑初级预防的隐患。
Clin Infect Dis. 1998 Jan;26(1):186-7. doi: 10.1086/517056.
4
In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.伏立康唑（UK-109,496）及其他四种抗真菌药物对394株念珠菌属临床分离株的体外活性
Antimicrob Agents Chemother. 1998 Jan;42(1):161-3. doi: 10.1128/AAC.42.1.161.
5
In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.新型三唑类药物伏立康唑（UK-109,496）对机会性丝状真菌和双相真菌以及常见和新出现的酵母病原体的体外活性。
J Clin Microbiol. 1998 Jan;36(1):198-202. doi: 10.1128/JCM.36.1.198-202.1998.
6
Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species.伏立康唑（UK-109,496）可抑制氟康唑敏感及耐药念珠菌属的生长并改变其形态。
Antimicrob Agents Chemother. 1997 Aug;41(8):1840-2. doi: 10.1128/AAC.41.8.1840.
7
In vitro evaluation of voriconazole against some clinically important fungi.伏立康唑对某些临床重要真菌的体外评价。
Antimicrob Agents Chemother. 1997 Aug;41(8):1832-4. doi: 10.1128/AAC.41.8.1832.
8
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.获得性免疫缺陷综合征相关隐球菌性脑膜炎的治疗。美国国立过敏和传染病研究所真菌病研究组及艾滋病临床试验组。
N Engl J Med. 1997 Jul 3;337(1):15-21. doi: 10.1056/NEJM199707033370103.
9
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.抗真菌药敏试验解释性断点的制定：氟康唑、伊曲康唑和念珠菌感染的体外-体内相关性数据的概念框架与分析。美国国家临床实验室标准委员会抗真菌药敏试验小组委员会
Clin Infect Dis. 1997 Feb;24(2):235-47. doi: 10.1093/clinids/24.2.235.
10
In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.新型三唑类抗真菌药物伏立康唑（UK-109,496）对新出现的及较少见霉菌病原体活性的体外研究。
Antimicrob Agents Chemother. 1997 Apr;41(4):841-3. doi: 10.1128/AAC.41.4.841.
Zotero 插件